Skip to main content

Table 1 Disease and survival data of seed inoculated hSOD1G85R Tg mice receiving systemic administration of mAbs

From: Aggregate-selective antibody attenuates seeded aggregation but not spontaneously evolving disease in SOD1 ALS model mice

  No mAb control αSOD165–72 (10 mg/kg) αSOD165–72 (50 mg/kg) αSOD1143–153 (10 mg/kg) αSOD1143–153 (50 mg/kg) pAb IgG (50 mg/kg)
n days n days n days n days n days n days
Age at 1st mAb injection 5 76 ± 2 5 76 ± 2 5 79 9 79 ± 3 9 78 ± 3
Age at SOD1G85R seed inoculation 9 100 ± 4 5 98 ± 2 5 99 ± 2 5 101 ± 1 9 101 ± 3 9 100 ± 3
Paralytic end-stage (days post-inoculation) 9 94 ± 14 5 88 ± 24 5 78 ± 2 5 118 ± 35 9 185 ± 101 9 113 ± 59
Symptom onset (days post-inoculation) 6 69 ± 13 5 73 ± 17 5 62 ± 5 5 100 ± 25 9 175 ± 102 9 101 ± 63
Age at paralytic end-stage 9 195 ± 13 5 187 ± 26 5 177 ± 3** 5 219 ± 35 9 286 ± 100**, * 9 214 ± 58
  1. For experimental outline and survival graph; see Fig. 3c, d
  2. All data are presented as mean ± SD
  3. – not applicable
  4. *p < 0.05 survival is significantly different compared to IgG control
  5. **p < 0.01 survival is significantly different compared to No mAb control
\